Authors : Priyanka; Lubna Fathima; Muthulakshmi S.; Dinesh Dhamodhar; Sindhu R; Prabu D.; Rajmohan M.

Volume/Issue : Volume 10 - 2025, Issue 11 - November

Google Scholar : https://tinyurl.com/27th9djn

Scribd : https://tinyurl.com/mujsabjw

DOI : https://doi.org/10.38124/ijisrt/25nov222

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Background: Estragole is a constituent of herbs such as tarragon, basil, and fennel. It is known for its anti-inflammatory and antimicrobial activity. There is evidence of its carcinogenic potential in animal models. Estragole carcinogenicity may be linked to its metabolic conversion, forming 1′-sulfoxy metabolites. These metabolites can form covalent DNA adducts, inducing hepatic tumors at high-dose repeated exposure in rodents.  Aim: This narrative review aimed to evaluate the carcinogenic potential of estragole by systematically analysing published animal trials and assessing the neoplastic changes.  Materials and Method: A systematic review was conducted using Pubmed, Elsevier Science Direct, Wiley Online library, Scopus data bases. The keywords “Estragole” and “Neoplasm” were used as MeSH terms. From the initially identified articles 296, 286 were screened after duplicate removal based on inclusion criteria (English language, Full-text articles, animal trial studies on the carcinogenic effect of estragole). 4 studies were selected for final analysis.  Results: The included animal trials investigated estragoles effect on mice and rats at various doses. Estragole was shown to have high carcinogenic potential at high doses. With an increase in estragole dosage, there was an increase in hepatic tumors in both mice and rats.  Conclusion: In rat and mice animal models, high dosage of estragole induces tumor formation. The risk of estragole for humans is presently not determined, as it is consumed at low ppm levels. Estragole is a potential carcinogenic agent. Further metabolic, and human related studies are needed to determine carcinogenic risk of estragole to human.

Keywords : Estragole, Cancer, Hepatocellular Carcinoma.

References :

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2024 May;74(3):229-63.
2. Dixon K, Kopras E. Genetic alterations and DNA repair in human carcinogenesis. InSeminars in cancer biology 2004 Dec 1 (Vol. 14, No. 6, pp. 441-448). Academic Press.
3. Kobets T, Smith BP, Williams GM. Food-borne chemical carcinogens and the evidence for human cancer risk. Foods. 2022 Sep 13;11(18):2828.
4. Abbott PJ. Carcinogenic chemicals in food: evaluating the health risk. Food and chemical toxicology. 1992 Apr 1;30(4):327-32.
5. Koshy A. Evolving global etiology of hepatocellular carcinoma (HCC): insights and trends for 2024. Journal of Clinical and Experimental Hepatology. 2025 Jan 1;15(1):102406.
6. Kew M. C. (2014). Hepatocellular carcinoma: epidemiology and risk factors. Journal of hepatocellular carcinoma, 1, 115–125. https://doi.org/10.2147/JHC.S44381
7. Acharya SK. Epidemiology of hepatocellular carcinoma in India. Journal of clinical and experimental hepatology. 2014 Aug 1;4:S27-33.
8. Singh SP, Madke T, Chand P. Global epidemiology of hepatocellular carcinoma. Journal of Clinical and Experimental Hepatology. 2025 Mar 1;15(2):102446.
9. Tu J, Wang B, Wang X, Huo K, Hu W, Zhang R, Li J, Zhu S, Liang Q, Han S. Current status and new directions for hepatocellular carcinoma diagnosis. Liver Research. 2024 Dec 1;8(4):218-36.
10. Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the definition of cancer. Molecular Cancer Research. 2023 Nov 1;21(11):1142-7.
11. Júnior EB, de Oliveira Formiga R, de Lima Serafim CA, Araruna ME, de Souza Pessoa ML, Vasconcelos RC, de Carvalho TG, de Jesus TG, Araújo AA, de Araujo Junior RF, Vieira GC. Estragole prevents gastric ulcers via cytoprotective, antioxidant and immunoregulatory mechanisms in animal models. Biomedicine & Pharmacotherapy. 2020 Oct 1;130:110578.
12. Bristol DW. NTP 3-month toxicity studies of estragole (CAS No. 140-67-0) administered by gavage to F344/N rats and B6C3F1 mice. Toxicity report series. 2011 Jan 1(82):1-11.
13. Nasaba EM, Athari SM, Motlagh B, Athari SS. Effects of oral administration of Ocimum basilicum on goblet cell hyperplasia and upstream cytokine gene expression in allergic asthma. Revue Française d'Allergologie. 2020 Mar 1;60(2):64-8.
14. Sestili P, Ismail T, Calcabrini C, Guescini M, Catanzaro E, Turrini E, Layla A, Akhtar S, Fimognari C. The potential effects of Ocimum basilicum on health: a review of pharmacological and toxicological studies. Expert opinion on drug metabolism & toxicology. 2018 Jul 3;14(7):679-92.
15. Mossanen JC, Kohlhepp M, Wehr A, Krenkel O, Liepelt A. Anjali A. Roeth, 4 Diana Möckel, 5 Felix Heymann, Twan Lammers, 5 Nikolaus Gassler, 6 Juliane Hermann, 7 Joachim Jankowski, 7 Ulf P. Neumann, 4 Tom Luedde, Christian Trautwein, and Frank Tacke1, 3. Gastroenterology. 2019;1:13.
16. Schulte-Hubbert R, Küpper JH, Thomas AD, Schrenk D. Estragole: DNA adduct formation in primary rat hepatocytes and genotoxic potential in HepG2-CYP1A2 cells. Toxicology. 2020 Nov 1;444:152566.
17. Yang S, Wesseling S, Rietjens IM. Estragole DNA adduct accumulation in human liver HepaRG cells upon repeated in vitro exposure. Toxicology Letters. 2021 Feb 1;337:1-6.
18. Smith RL, Adams TB, Doull J, Feron VJ, Goodman JI, Marnett LJ, Portoghese PS, Waddell WJ, Wagner BM, Rogers AE, Caldwell J. Safety assessment of allylalkoxybenzene derivatives used as flavouring substances—methyl eugenol and estragole. Food and chemical Toxicology. 2002 Jul 1;40(7):851-70.
19. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71.
20. Puljak L. Adequate and complete reporting of Cochrane risk of bias tool. Pain 2019;160:984.
21. Handbook for Conducting a Literature-Based Health Assessment Using OHAT Approach for Systematic Review and Evidence Integration (2nd ed.). (2019). National Institute of Environmental Health Sciences. (Original work published 2015).
22. Drinkwater NR, Miller EC, Miller JA, Pitot HC. Hepatocarcinogenicity of estragole (1-allyl-4-methoxybenzene) and 1′-hydroxyestragole in the mouse and mutagenicity of 1′-acetoxyestragole in bacteria. Journal of the National Cancer Institute. 1976 Dec 1;57(6):1323-31
23. Wiseman RW, Miller EC, Miller JA, Liem A. Structure-activity studies of the hepatocarcinogenicities of alkenylbenzene derivatives related to estragole and safrole on administration to preweanling male C57BL/6J× C3H/HeJ F1 mice. Journal of Ethnopharmacology. 1988 Apr 1;22(3):319.